BSX - Boston Scientific Corp Volatility & Greeks
This article provides a detailed overview of Boston Scientific Corp (BSX) including its stock performance, financial metrics, valuation ratios, and volatility indicators. It lists key data such as market capitalization, income, sales, price-to-earnings ratio, and various growth rates. The information is presented in a data-rich format, characteristic of financial screening platforms, without narrative commentary.
Intuitive Surgical Stock Looks Weighed Down. Its After-Hours Growth Says Otherwise.
Intuitive Surgical (ISRG) stock has seen a 26% decline over the last year, primarily due to concerns about slowing elective surgeries and the impact of GLP-1 weight-loss drugs. However, the company is experiencing significant growth in U.S. after-hours procedures, which are non-elective acute care surgeries, growing 31% year-over-year. This expansion into emergency procedures provides a new, resilient growth vector, demonstrating the da Vinci platform's versatility beyond scheduled operations and fueling high-margin recurring revenue.
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
Johnson & Johnson's (J&J) MedTech division is anticipated to report strong growth in Q2 2026, driven by recent acquisitions in cardiovascular health and new product launches, particularly in electrophysiology. Despite challenges from China's volume-based procurement program, the segment's performance, especially in Cardiovascular, Surgery, and Vision, is expected to reinforce investor confidence in its long-term growth potential. J&J's shares have outperformed the industry this year but are currently valued slightly higher than the industry average.
Top 10 medtech deals in the first half of 2026
Medtech companies engaged in significant merger and acquisition activity during the first half of 2026, building on previous high deal volumes. This period saw $36.5 billion in acquisitions, with companies like Boston Scientific, Medtronic, and Stryker making strategic moves to enter fast-growing markets or divest from slower areas. The top deal was Boston Scientific's $14.5 billion acquisition of Penumbra, alongside other notable transactions by Danaher, Roche, and Agilent.
Medtronic Plc (MDT) Stock Analysis: Healthcare Giant Offers A 17.53% Upside Potential
Medtronic Plc (MDT) is presented as a compelling investment opportunity in the healthcare sector, particularly medical devices, with a market capitalization of $106.49 billion and a stock price of $83.19. The company exhibits robust financial health with 9.90% revenue growth, a 3.46% dividend yield, and over $4.6 billion in free cash flow. Analyst ratings are largely positive, with no sell ratings and an average target price suggesting a 17.53% upside potential.
Catheter Precision, Inc. Announces Issuance of Two Key Patents
Catheter Precision, Inc. (VTAK) has announced the issuance of two new patents related to its medical device technologies. One patent covers European intellectual property for its VIVO technology, aimed at precisely locating cardiac arrhythmias using implantable device data, joining 18 existing patents and applications for VIVO. The second patent is part of the Cardionomix heart failure portfolio, focusing on systems and methods for denoising physiological signals during electrical neuromodulation for acute decompensated heart failure treatment, bringing that portfolio to 33 patents and applications.
Medtronic plc highlights its global medical technology role as investors monitor long-term growth
Medtronic plc, a major player in medical devices, is highlighted for its diversified portfolio and role in global medical technology. Investors focus on the company's long-term growth driven by recurring revenue from implanted therapies, innovation, and its engagement with digital health trends. The article discusses Medtronic's global footprint, revenue drivers, operational efficiency, and the structural tailwinds of an aging population, set against risk considerations like regulatory shifts and pricing pressures.
Price to earnings forward of Medtronic Plc – MIL:1MDT
This article provides the "Price to earnings forward" value for Medtronic Plc (MIL:1MDT) sourced from TradingView. It specifies that the market is currently closed with no trades. The content is primarily a data placeholder and navigational structure from a financial platform.
Price to earnings forward of Medtronic plc. – NYSE:MDT
This article provides the "Price to earnings forward" value for Medtronic plc. (NYSE: MDT). The data is sourced from FactSet Research Systems Inc. and is current as of 2026, indicating a specific financial metric for the health technology company.
EW - Edwards Lifesciences Corp Volatility & Greeks
This article provides a detailed financial overview of Edwards Lifesciences Corp (EW), including its stock performance, market capitalization, income, sales, and various financial ratios. It also presents insider ownership and institutional ownership data, along with volatility measures and analyst recommendations. The data indicates strong recent performance and growth projections for the company.
Medtronic Notifies 3.8 Million After ShinyHunters Data Breach
Medtronic is notifying over 3.8 million people that their personal and medical data may have been exposed following a cyberattack by the ShinyHunters extortion group in April 2026. The breached data could include names, contact details, dates of birth, Social Security numbers, and health information, although Medtronic states there's no evidence the data has been publicly released. The company is offering 24 months of free credit monitoring and identity theft services to affected individuals.
Enterprise value to EBITDA forward of Medtronic plc. – NYSE:MDT
The article focuses on Medtronic plc. (NYSE: MDT) and its Enterprise Value to EBITDA forward metric. It provides specific data related to this financial ratio over various periods and highlights the value changes and percentages for Medtronic.
Globus Medical (GMED) Secures FDA Clearances As Revenue And R And D Stay Strong
Globus Medical (GMED) has secured new FDA clearances, expanding its product offerings in spine and orthopedic surgery. This development, coupled with strong revenue growth and a steady commitment to R&D, positions the company as an innovative and high-growth investment, especially when compared to competitors like Medtronic. An analysis by Simply Wall St suggests GMED shares are currently undervalued, trading significantly below analyst targets and their estimated fair value.
Enterprise value to EBITDA forward of Medtronic Plc – MIL:1MDT
This article provides the enterprise value to EBITDA forward for Medtronic Plc (MIL:1MDT). It includes a brief header indicating the stock ticker, exchange, and market status. The content also includes various disclaimers regarding data sources and copyrights.
Cardinal Health Kangaroo Joey Enteral Feeding Pump - A long-running workhorse in U.S. hospitals
The article highlights the Cardinal Health Kangaroo Joey Enteral Feeding Pump as a foundational product in U.S. hospitals and home care, valued for its reliability, compact design, and ease of use. It details the pump's features, clinical utility, and role in Cardinal Health's medical segment revenue, emphasizing its "longseller" status due to consistent performance and integration into healthcare workflows. The piece also touches on regulatory compliance, competitive landscape, and the pump's financial significance for Cardinal Health.
MDT - Medtronic Plc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Medtronic Plc (MDT). It includes detailed financial metrics such as market capitalization, income, sales, dividend information, various valuation ratios, and performance indicators. The report also highlights institutional and insider ownership, analyst recommendations, and recent stock performance.
Teleflex Q1 2026 slides: earnings beat amid margin pressure, buyback starts early
Teleflex (NYSE: TFX) exceeded Q1 2026 earnings and revenue expectations despite significant margin pressure from tariffs and integration costs. The company reported adjusted EPS of $1.39 and revenue of $548.3 million, driven by strong performance in the Surgical segment and the recent Vascular Intervention acquisition. Teleflex also announced new leadership, governance enhancements, and an accelerated $1 billion share repurchase authorization starting in Q2 2026, while maintaining its full-year 2026 guidance.
Russell Growth Index Exit Could Be A Game Changer For Stryker’s (SYK) Investor Base
Stryker Corporation (NYSE: SYK) was recently removed from several major Russell growth indexes, including the Russell 1000 Growth, Russell Top 200 Growth, and Russell 3000 Growth benchmarks. This move is significant not for the company's underlying business fundamentals, but for how its stock might trade and who its investors will be. The upcoming Q2 2026 earnings webcast on July 30 will be key for investors to understand how Stryker is managing supply chain issues and input costs.
KIDS,ATEC Volatility & Greeks
The article provides detailed financial and performance data for two medical device companies: OrthoPediatrics Corp (KIDS) and Alphatec Holdings Inc (ATEC). It includes current stock prices, market capitalization, earnings per share, sales figures, institutional and insider ownership, and various other financial ratios and performance metrics for both companies as of July 2nd.
PEN - Penumbra Inc Volatility & Greeks
This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and historical performance over different periods.
Intuitive Surgical (ISRG) Stock Looks Fully Priced After Its 34% Five Year Gain
Intuitive Surgical (ISRG) has seen a 34.4% gain over the past five years, but current valuations suggest the stock is fully priced to expensive. While a Discounted Cash Flow (DCF) model indicates the stock is roughly at fair value, its high P/E ratio compared to the Medical Equipment industry points to overvaluation. Investors are left to weigh whether the company's strong cash flow and robotic surgery ecosystem can justify its premium multiples amidst regulatory scrutiny and competition.
SIBN - SI-BONE Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for SI-BONE Inc (SIBN), including its latest stock price, market capitalization, earnings per share, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and recent price performance over different periods. The information is presented as a snapshot of the company's financial health and stock market activity.
Intuitive Surgical Is Down 28%, and Wall Street Is Piling On. Goldman Sachs Just Said Everyone Is Wrong -- and History Is on Its Side.
Intuitive Surgical (NASDAQ: ISRG) stock has dropped 28% this year, causing concern among investors and leading several analysts to downgrade their positions. However, Goldman Sachs analyst David Roman argues that the panic is based on a misunderstanding of the company's changes to instrument lifetimes. Roman believes history indicates a recovery, maintaining a price target of $558, suggesting that premium instruments will offset revenue adjustments from extended tool lifespans.
Intuitive Surgical Is Down 28%, and Wall Street Is Piling On. Goldman Sachs Just Said Everyone Is Wrong -- and History Is on Its Side.
Intuitive Surgical (NASDAQ: ISRG) stock has dropped 28% this year, causing anxiety among investors and leading several analysts to downgrade their positions. However, Goldman Sachs analyst David Roman increased the stock's price target to $558, arguing that concerns stemming from changes to the company's instrument lifetimes are misunderstood and that historically, such changes have not significantly impacted revenue. The company's underlying business remains robust, with strong growth in procedures and installed surgical systems, though its premium valuation requires careful monitoring.
Why Is Medtronic (MDT) Up 1.5% Since Last Earnings Report?
Medtronic (MDT) shares have increased by 1.5% since its last earnings report, outperforming the S&P 500. The company reported Q4 fiscal 2026 adjusted earnings of $1.55 per share and revenue of $9.81 billion, both exceeding estimates, driven by strong procedure-driven demand. Despite a positive outlook for fiscal 2027 and a dividend increase, Zacks Investment Research currently gives MDT a "Sell" rating.
ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook
ResMed (RMD) saw its stock rise by 5.6% following its removal from several Russell growth indices, including the Russell 1000 Growth and Russell Midcap Growth benchmarks. This occurred as analysts became more optimistic about the company's earnings outlook, with upgraded rankings and higher profit estimates. The article suggests that while index removal primarily affects index flows, the improving analyst sentiment and upcoming Q4 fiscal 2026 earnings report on August 6 could significantly reshape ResMed's investment narrative.
Medtronic starts to notify people affected by cyberattack
Medtronic has begun notifying individuals affected by a cyberattack disclosed over two months ago, offering 24 months of complimentary credit and dark web monitoring, and identity theft restoration services. The company states there is no evidence the accessed data has been publicly posted and no impact on product security or patient safety. This incident follows a string of cyberattacks affecting other medtech companies like Stryker, Intuitive Surgical, and iRhythm this year.
Medtronic PLC stock outperforms competitors on strong trading day
Medtronic PLC stock (MDT) advanced 5.04% to $83.19 on Thursday, outperforming its competitors and marking its second consecutive day of gains. This performance occurred during a mixed trading session where the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average rose by 1.14%.
Medtronic starts to notify people affected by cyberattack
Medtronic has begun notifying individuals potentially affected by a cyberattack disclosed over two months ago, offering complimentary credit monitoring and identity theft services. The company states there is no evidence the accessed data has been publicly posted, and no impact on product security or patient safety has been identified. This incident follows a string of cyberattacks on other medtech companies, including Stryker, Intuitive Surgical, and iRhythm, highlighting an ongoing industry-wide vulnerability.
PHG - Koninklijke Philips NV ADR Volatility & Greeks
This article provides a detailed financial overview of Koninklijke Philips NV ADR (PHG), including its current stock performance, key financial metrics, EPS trends, and insider/institutional ownership data. It presents a snapshot of the company's market position, dividend information, and analyst recommendations.
PHG - Koninklijke Philips NV ADR Earnings
This article provides a detailed financial overview of Koninklijke Philips NV (PHG) ADR, including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, and analyst recommendations.
Hologic removes BioZorb 3D bioabsorbable markers due to safety reasons
Hologic, Inc. is recalling its BioZorb Marker due to a significant number of reported complications and adverse events, including pain, infection, and device migration, though no deaths have occurred. The implantable radiographic marker, used to identify soft tissues like breast tissue for medical procedures, consists of both permanent titanium and resorbable plastic components. The recall comes after 252 reported injuries were linked to the device.
What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders
Tandem Diabetes Care recently expanded its t:slim X2 insulin pump's compatibility with Abbott's FreeStyle Libre 3 Plus CGM in Europe, while facing new competition from Modular Medical's Pivot tubeless insulin patch pump. This dual development highlights both the growth of Tandem's ecosystem and increasing competitive pressures in the insulin delivery market. The article suggests this situation could lead to a mix of international expansion opportunities and risks from new tubeless rivals for Tandem shareholders.
Medtronic plc (MDT) & Retia Expand Partnership to Target High-Risk Surgical and Critically ill Patients
Medtronic plc (MDT) has expanded its partnership with cardiovascular intelligence software company Retia Medical to distribute the Argos Cardiac Output Monitor. This collaboration aims to leverage Medtronic's Acute Care & Monitoring Technologies to enhance care for high-risk surgical and critically ill patients, with an initial focus on expanding into the European market. Medtronic's involvement will help Retia broaden its reach and integrate advanced hemodynamic monitoring into clinical practice.
Medtronic plc (MDT) & Retia Expand Partnership to Target High-Risk Surgical and Critically ill Patients
Medtronic and Retia Medical have expanded their commercial partnership to distribute the Argos Cardiac Output Monitor, aiming to provide advanced hemodynamic monitoring for high-risk surgical and critically ill patients. This collaboration will help Retia enter new markets, particularly in Europe, and integrate its technology with Medtronic's acute care solutions. Medtronic, a global healthcare technology leader, seeks to enhance personalized patient care with this new offering.
Price to sales forward of Medtronic Plc – MIL:1MDT
This page displays the "Price to sales forward" financial metric for Medtronic Plc (MIL:1MDT). It indicates that the market was closed with no trades at the time the data was accessed. The content is part of a larger financial data platform by TradingView, sourcing data from ICE Data Services and FactSet.
Medtronic PLC stock outperforms competitors on strong trading day
Shares of Medtronic PLC (MDT) rose 1.24% to $79.20 on a day when the S&P 500 Index and Dow Jones Industrial Average both fell. This performance allowed Medtronic PLC to outperform its competitors during a generally dismal trading session. The stock's gain ended a two-day losing streak for the company.
Nnamdi Njoku Appointed President of Omnicell
Omnicell, Inc. has announced the appointment of Nnamdi Njoku as President, effective July 1, 2026. Njoku will continue in his role as Chief Operating Officer, while Randall Lipps remains Chief Executive Officer and Chairman of the Board. In his expanded role, Njoku will lead Omnicell's long-term growth strategy, innovation roadmap, and global operations, focusing on product, innovation, and customer experience, including the launch of Omnicell Titan XT and expansion of the OmniSphere platform.
Nnamdi Njoku appointed President of Omnicell (OMCL) while Randall Lipps remains CEO
Omnicell, Inc. has appointed Nnamdi Njoku as President, effective July 1, 2026, where he will also continue in his role as Chief Operating Officer. Randall A. Lipps will step down from the President role but will remain Chief Executive Officer and Chairman of the Board, with no changes to his compensation. Njoku will focus on Omnicell's long-term growth strategy, global operations scaling, and product innovation, including initiatives like the Omnicell Titan XT system and the OmniSphere platform.
LMAT - Lemaitre Vascular Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Lemaitre Vascular Inc (LMAT). It includes current stock performance metrics, key financial ratios, insider and institutional ownership data, and various performance indicators across different timeframes. The company's stock closed at $98.74, up 2.90% on July 1st.
Is Intuitive Surgical Stock a Buy Now After Falling 29% Year to Date?
Intuitive Surgical (ISRG) delivered strong Q1 2026 results, beating Street estimates for revenue and EPS, driven by significant procedure volume growth across its platforms. Despite a 29% year-to-date fall in its stock price, analysts maintain a consensus "buy" rating with a mean target implying 42% upside. TIKR's mid-case model values ISRG at $675 by December 2030, projecting a 70% total return, based on continued utilization of its new da Vinci systems and growth in other platforms, even with headwinds in China and Japan.
PODD - Insulet Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Insulet Corp (PODD). It details key financial metrics, stock performance, analyst recommendations, and insider transaction information, offering a snapshot of the company's current market standing.
DXCM - Dexcom Inc Latest SEC Filings
This article provides the latest SEC filings information and comprehensive financial data for Dexcom Inc (DXCM). It details the company's recent stock performance, key financial metrics such as market cap, income, sales, P/E ratio, and growth rates. The information also includes insider and institutional ownership, profitability margins, and analyst recommendations.
TNDM - Tandem Diabetes Care Inc Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Tandem Diabetes Care Inc. (TNDM). It highlights key figures such as the last closing price, market capitalization, income, sales, various financial ratios, and stock performance over different periods. The data indicates recent stock movement, insider and institutional ownership, and profitability margins.
NVCR - NovoCure Ltd Volatility & Greeks
This article provides a detailed financial overview of NovoCure Ltd (NVCR), including its stock performance, key financial metrics, and volatility. It highlights the company's market capitalization, income, sales, and various financial ratios, alongside insider ownership and institutional transactions. The data also covers its recent stock changes, volume, and performance over different periods.
Medtronic PLC Stock (MDT) Closed Down by 3.30% on Jun 30: Key Drivers Unveiled
Medtronic PLC (MDT) stock closed down 3.30% on June 30 due to a broader capital rotation out of defensive healthcare stocks into growth sectors, disappointing fiscal 2027 guidance, and increased trading volatility from FTSE Russell index reconstitution and ex-dividend adjustments. The company faces ongoing challenges including tariff headwinds, regulatory recalls, and intense competition in surgical robotics, despite some positive technical indicators. Analysts maintain a mixed view, with an average price target of $97.91, but significant bearish options activity suggests caution.
Stryker (SYK) Stock After Recent Pullback And DCF Upside Potential
Stryker (SYK) stock has seen mixed performance recently, with an 8.5% rise over the last week but a 15.6% decline year-over-year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 12.8%, with an intrinsic value of $379.17 per share against its current price of $330.52. However, its Price-to-Earnings (P/E) ratio of 37.97x is higher than the industry average, indicating it might be overvalued by this metric when compared to Simply Wall St's Fair Ratio of 31.39x.
Medtronic PLC stock underperforms Tuesday when compared to competitors
Shares of Medtronic PLC (MDT) fell 3.34% on Tuesday, closing at $78.23. This underperformance occurred on an otherwise positive trading day for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. This marks the second consecutive day of losses for Medtronic's stock.
EW - Edwards Lifesciences Corp Latest SEC Filings
This article provides the latest SEC filing information for Edwards Lifesciences Corp (EW), detailing various financial metrics, stock performance data, and insider/institutional ownership figures. It also includes key company statistics such as market cap, P/E ratio, sales, and employee count, alongside a summary of recent earnings and sales performance.
Orchestra BioMed Joins Russell 3000 and Russell 2000 Indexes
Orchestra BioMed Holdings, Inc. has been added to the Russell 3000 and Russell 2000 Indexes, effective July 1, 2026, as part of the annual reconstitution. This inclusion is expected to increase the company's visibility within the investment community. The Russell indexes are widely used benchmarks for institutional investors, and companies remain on them for one year.
